Fosun Pharma

News

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.